logo-loader
LON:AVCT

Avacta Group PLC

Receive alerts
Market:
LON
Market Cap:
£25.56 m
Price
£0.22
Change
-1.10%
52 weeks high
49.80
52 weeks low
21.00

Viewing results 1-25 of 80

Health

Avacta teams up with Selexis to develop Chinese hamster ovary cell line

On the tie-up with Selexis, Avacta chief executive Alastair Smith said the company's new partner provided “the technology and know-how” to develop the required cell lines for the planned first-in-human study...

on 20/6/19
Health

Avacta selects drug candidate for phase I trial

The important milestone puts the company on track to file a new drug/clinical application by the end of 2020 as planned...

on 10/6/19
Health

Avacta plans for exciting cancer immunotherapy

The group's technology releases chemo directly inside a tumour without exposing the whole body to toxins ...

on 3/6/19
Health

Analysts eye more licensing deals for Avacta’s Affimer technology in 2019

Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences ...

on 2/5/19
Health

Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year

The first Affimer-based therapeutic is PD-L1 is a potential cancer treatment that helps the immune system to identify and attack cancer cells...

on 9/4/19
Health

Avacta - interim results confirm progress

Avacta Group PLC (LON:AVCT) reported interim results to January 2019, confirming good progress on key development programmes Lead immune checkpoint inhibitor programmes continue to move towards in-man clinical data in 2020 Major development partnership and......

on 9/4/19
Health

Avacta says partner Moderna takes collaboration to next level

The US-listed group has triggered an exclusivity option. Chief executive Dr Alastair Smith said: "This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development"...

on 5/2/19
Health

Avacta Group trading in line in "year of very significant progress"

An update on the collaboration with Moderna is planned for the first half of this year...

on 21/1/19
Health

Avacta appoints industry heavyweight as chief medical officer

Dr Jose Saro is joining the business from the Roche Innovation Center...

on 12/12/18
Health

Avacta soars after signing partnership deal with Korea's LG Group

The Affimer technology is Avacta's proprietary alternative to antibodies with wide applications in the life sciences for drug development, diagnostics and research tools...

on 11/12/18
Health

Avacta’s Affimer tech gains traction as it clinches deal with “very high quality partner”

The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year...

on 29/11/18
Health

Avacta’s CTO to present Affimer data at Biomarkers and Precision Medicine Congress

The biotech company said Dr Matt Johnson would present data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays...

on 11/10/18
Health

Avacta rises as it secures licensing deal with New England Biolabs for Affimer technology

The biotechnology firm said it had been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis)...

on 10/10/18